首页 > 最新文献

Current Psychopharmacology最新文献

英文 中文
Psilocybin in the Management of Substance Use Disorders: A Summary ofCurrent Evidence 治疗药物使用障碍的迷幻剂:当前证据摘要
Pub Date : 2024-07-03 DOI: 10.2174/0122115560288779240628043307
Hussein El Bourji, Aziz Farhat, Zahi Hamdan, Ritvij M Satodiya, Rashmi Shukla, S. El Hayek
Following clinical trials on psilocybin for the treatment of pain, anxiety,and depression in patients with cancer, scientific interest emerged in its use for substance use disorders.In this review of the literature, we summarize available trials looking at the use of psilocybin in addictionOne double-blind, randomized clinical trial looked at the effect of psilocybin on heavydrinking in adults diagnosed with alcohol dependence. Several trials are currently ongoing to assesspsilocybin’s efficacy in the management of different SUDs. Otherwise, the current evidence is insufficient to derive any conclusions on the possible efficacy of psilocybin in substance use disorders.More well-powered, blinded, randomized controlled trials are needed to investigatethe possible therapeutic effects of psilocybin in addiction while identifying the appropriate conditions that promote its safe use.
一项双盲随机临床试验研究了西洛赛宾对被诊断为酒精依赖症的成年人大量饮酒的影响。目前正在进行几项试验,以评估迷幻药在治疗不同的成瘾性疾病方面的疗效。此外,目前的证据还不足以就迷幻药对药物使用障碍可能产生的疗效得出任何结论。需要进行更多有充分证据支持的盲法随机对照试验,以研究迷幻药对成瘾可能产生的治疗效果,同时确定促进安全使用迷幻药的适当条件。
{"title":"Psilocybin in the Management of Substance Use Disorders: A Summary of\u0000Current Evidence","authors":"Hussein El Bourji, Aziz Farhat, Zahi Hamdan, Ritvij M Satodiya, Rashmi Shukla, S. El Hayek","doi":"10.2174/0122115560288779240628043307","DOIUrl":"https://doi.org/10.2174/0122115560288779240628043307","url":null,"abstract":"\u0000\u0000Following clinical trials on psilocybin for the treatment of pain, anxiety,\u0000and depression in patients with cancer, scientific interest emerged in its use for substance use disorders.\u0000\u0000\u0000\u0000In this review of the literature, we summarize available trials looking at the use of psilocybin in addiction\u0000\u0000\u0000\u0000One double-blind, randomized clinical trial looked at the effect of psilocybin on heavy\u0000drinking in adults diagnosed with alcohol dependence. Several trials are currently ongoing to assess\u0000psilocybin’s efficacy in the management of different SUDs. Otherwise, the current evidence is insufficient to derive any conclusions on the possible efficacy of psilocybin in substance use disorders.\u0000\u0000\u0000\u0000More well-powered, blinded, randomized controlled trials are needed to investigate\u0000the possible therapeutic effects of psilocybin in addiction while identifying the appropriate conditions that promote its safe use.\u0000","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"22 s43","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141683743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Have We Placed the Cart Before the Horse by Using Alpha-2 Agonists toTreat Rejection Sensitivity Dysphoria in ADHD? 使用 Alpha-2 激动剂治疗多动症患者的拒绝敏感性失调症,我们是否本末倒置了?
Pub Date : 2024-04-05 DOI: 10.2174/0122115560297397240404071044
William W. Dodson, E. Modestino
{"title":"Have We Placed the Cart Before the Horse by Using Alpha-2 Agonists to\u0000Treat Rejection Sensitivity Dysphoria in ADHD?","authors":"William W. Dodson, E. Modestino","doi":"10.2174/0122115560297397240404071044","DOIUrl":"https://doi.org/10.2174/0122115560297397240404071044","url":null,"abstract":"<jats:sec>\u0000<jats:title />\u0000<jats:p />\u0000</jats:sec>","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"72 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140736265","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Neuroanatomy, Etiopathogenesis, and Novel Therapeutic Targets inDepressive Disorders 抑郁障碍的神经解剖、发病机制和新型治疗靶点
Pub Date : 2024-01-19 DOI: 10.2174/0122115560281804240102054639
Indu Arora, Kunal Khurana, Manish Kumar
Depression has a high prevalence and associated comorbidities. It is still unknown whatthe molecular basis of depression is, regardless of many theories that have been put up to explain it.Many researchers investigate that present-day therapies for depression are ineffective due to theirlow efficacy, delayed onset of action (typically two weeks), and adverse effects. Novel medicationsthat operate more quickly and effectively are thus needed. Several novel molecules (e.g., ketamine,buprenorphine) have been proven to produce quick and dependable antidepressant benefits in depressivepatients who are resistant to treatment; yet, questions about their effectiveness, possibleabuse, and adverse effects persist. The molecular basis and pharmacological interventions for depressionwere included in this study. Even if pharmaceutical treatments for depression have mostlyfailed to alleviate the condition, identifying and addressing possible risk factors in an effort to reducethe prevalence of this psychiatric disease is beneficial for public health. We emphasized theneuroanatomy and etiopathogenesis of depression, along with a discussion of the putative pharmacologicalmechanisms, novel targets, research hurdles, and prospective therapeutic futures.
抑郁症的发病率很高,并伴有多种并发症。许多研究人员调查发现,目前治疗抑郁症的药物疗效不佳,起效时间较晚(通常为两周),且存在不良反应。因此,我们需要更快、更有效的新型药物。有几种新型分子药物(如氯胺酮、丁丙诺啡)已被证实能对耐药的抑郁症患者产生快速、可靠的抗抑郁疗效;然而,有关其有效性、可能的滥用和不良反应的问题依然存在。本研究包括抑郁症的分子基础和药物干预。尽管抑郁症的药物治疗大多无法缓解病情,但识别和解决可能的风险因素,努力降低这种精神疾病的患病率,对公共健康是有益的。我们强调了抑郁症的神经解剖学和发病机理,并讨论了推测的药理机制、新靶点、研究障碍和治疗前景。
{"title":"The Neuroanatomy, Etiopathogenesis, and Novel Therapeutic Targets in\u0000Depressive Disorders","authors":"Indu Arora, Kunal Khurana, Manish Kumar","doi":"10.2174/0122115560281804240102054639","DOIUrl":"https://doi.org/10.2174/0122115560281804240102054639","url":null,"abstract":"\u0000\u0000Depression has a high prevalence and associated comorbidities. It is still unknown what\u0000the molecular basis of depression is, regardless of many theories that have been put up to explain it.\u0000Many researchers investigate that present-day therapies for depression are ineffective due to their\u0000low efficacy, delayed onset of action (typically two weeks), and adverse effects. Novel medications\u0000that operate more quickly and effectively are thus needed. Several novel molecules (e.g., ketamine,\u0000buprenorphine) have been proven to produce quick and dependable antidepressant benefits in depressive\u0000patients who are resistant to treatment; yet, questions about their effectiveness, possible\u0000abuse, and adverse effects persist. The molecular basis and pharmacological interventions for depression\u0000were included in this study. Even if pharmaceutical treatments for depression have mostly\u0000failed to alleviate the condition, identifying and addressing possible risk factors in an effort to reduce\u0000the prevalence of this psychiatric disease is beneficial for public health. We emphasized the\u0000neuroanatomy and etiopathogenesis of depression, along with a discussion of the putative pharmacological\u0000mechanisms, novel targets, research hurdles, and prospective therapeutic futures.\u0000","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"13 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139613782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Comprehensive Review on the Neuropharmacological Effects of Antidepressants in Various Prospects 抗抑郁药的神经药理作用综述
Pub Date : 2023-08-07 DOI: 10.2174/2211556011666230707122341
Sandesh Varshney, Md. Aftab Alam, Awaneet Kaur, Shaweta Sharma
Abstract: Depression is one of the most challenging diseases for society to treat. It is a highly prevalent and disabling illness in the general population. Affective disorders are characterised by depressed mood, diminished interest and pleasure, feelings of guilt or poor self-worth, sleep or food difficulties, decreased energy, and impaired attention. This manuscript will look at depression from a behavioural analytic perspective. The pathogenesis of major depressive disorder is poorly understood. Several lines of experimental and clinical evidence, however, show that the therapeutic effect of most antidepressant drugs is related to an increase in 5-HT-mediated neurotransmission. Alternative techniques, however, are employed to obtain this net effect. A better understanding of the neurological mechanism underpinning antidepressant drugs' delayed onset of action has resulted in the development of ways to accelerate antidepressant responses, which are discussed further below. Many antidepressant medications on the market today are beneficial, but they come with many downsides, including unpleasant side effects, potential interactions, and a low response rate. Natural drugs, on the other hand, are extremely effective, have a low risk, and a limited amount of side effects, which are covered briefly in this paper. Alternative modalities of administration have received a lot of attention in recent decades as a complement to approved prescription pharmaceuticals, especially for people who cannot tolerate oral or parenteral methods. The most promising non-invasive systemic delivery techniques are transdermal and transbronchial administration, and these are the focus of this research.
摘要:抑郁症是当今社会最具挑战性的疾病之一。这是一种在普通人群中非常普遍且致残的疾病。情感性障碍的特征是情绪低落、兴趣和愉悦感减退、内疚感或自我价值感差、睡眠或饮食困难、精力下降和注意力受损。这份手稿将从行为分析的角度来看待抑郁症。重性抑郁症的发病机制尚不清楚。然而,几条实验和临床证据表明,大多数抗抑郁药物的治疗效果与5- ht介导的神经传递的增加有关。然而,可以采用替代技术来获得这种净效果。对抗抑郁药物延迟起效的神经机制的更好理解导致了加速抗抑郁反应的方法的发展,这将在下面进一步讨论。目前市场上的许多抗抑郁药物都是有益的,但它们也有许多缺点,包括令人不快的副作用、潜在的相互作用和低反应率。另一方面,天然药物非常有效,风险低,副作用有限,本文将简要介绍。近几十年来,替代给药方式作为批准的处方药的补充受到了很多关注,特别是对于不能耐受口服或非肠道方法的人。最具前景的非侵入性全身给药技术是经皮和经支气管给药,这也是本研究的重点。
{"title":"A Comprehensive Review on the Neuropharmacological Effects of Antidepressants in Various Prospects","authors":"Sandesh Varshney, Md. Aftab Alam, Awaneet Kaur, Shaweta Sharma","doi":"10.2174/2211556011666230707122341","DOIUrl":"https://doi.org/10.2174/2211556011666230707122341","url":null,"abstract":"Abstract: Depression is one of the most challenging diseases for society to treat. It is a highly prevalent and disabling illness in the general population. Affective disorders are characterised by depressed mood, diminished interest and pleasure, feelings of guilt or poor self-worth, sleep or food difficulties, decreased energy, and impaired attention. This manuscript will look at depression from a behavioural analytic perspective. The pathogenesis of major depressive disorder is poorly understood. Several lines of experimental and clinical evidence, however, show that the therapeutic effect of most antidepressant drugs is related to an increase in 5-HT-mediated neurotransmission. Alternative techniques, however, are employed to obtain this net effect. A better understanding of the neurological mechanism underpinning antidepressant drugs' delayed onset of action has resulted in the development of ways to accelerate antidepressant responses, which are discussed further below. Many antidepressant medications on the market today are beneficial, but they come with many downsides, including unpleasant side effects, potential interactions, and a low response rate. Natural drugs, on the other hand, are extremely effective, have a low risk, and a limited amount of side effects, which are covered briefly in this paper. Alternative modalities of administration have received a lot of attention in recent decades as a complement to approved prescription pharmaceuticals, especially for people who cannot tolerate oral or parenteral methods. The most promising non-invasive systemic delivery techniques are transdermal and transbronchial administration, and these are the focus of this research.","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"25 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135840238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardio-Pshyco-Pharmacology: A Review 心脏-心理-药理学:综述
Pub Date : 2023-03-30 DOI: 10.2174/2211556011666230330094933
Dulaanga Rathnayake, A. A. N. Nishad, Sepalika Mendis
Cardiovascular and psychiatric diseases are leading causes of morbidity and mortality worldwide. Cardiovascular adverse events related to psychopharmacology have been well-known for decades. They increase the cardio-metabolic risk factor profile. Obesity, hypertension, diabetes mellitus (DM), and dyslipidemia are highly prevalent among patients with psychiatric disorders. Clozapine and olanzapine are known to cause severe hypertriglyceridemia. Drugs, such as aripiprazole, clozapine, olanzapine, and ziprasidone, increase the prevalence of hypertension, and atypical antipsychotics are known to cause orthostatic hypotension. The most common and popular arrhythmia, Torsades de pointes, due to QT prolongation, is a known side effect of typical and atypical antipsychotics. Sudden deaths, myocarditis, and cardiomyopathies are other common cardiac side effects of psycopharmacotherapy. Thus, pharmacovigilance is more important for both psychiatrists and cardiologists/physicians when evaluating patients with these common presentations and not to miss the etiological agents.
心血管和精神疾病是全世界发病率和死亡率的主要原因。几十年来,与精神药理学相关的心血管不良事件已经广为人知。它们增加了心脏代谢风险因素。肥胖、高血压、糖尿病(DM)和血脂异常在精神障碍患者中非常普遍。氯氮平和奥氮平可引起严重的高甘油三酯血症。阿立哌唑、氯氮平、奥氮平和齐拉西酮等药物会增加高血压的患病率,而非典型抗精神病药物已知会引起直立性低血压。最常见和最流行的心律失常,由于QT间期延长,是典型和非典型抗精神病药物的已知副作用。猝死、心肌炎和心肌病是精神药物治疗的其他常见心脏副作用。因此,对于精神科医生和心脏病专家/医生来说,在评估这些常见症状的患者时,药物警戒更重要,不要错过病因。
{"title":"Cardio-Pshyco-Pharmacology: A Review","authors":"Dulaanga Rathnayake, A. A. N. Nishad, Sepalika Mendis","doi":"10.2174/2211556011666230330094933","DOIUrl":"https://doi.org/10.2174/2211556011666230330094933","url":null,"abstract":"\u0000\u0000Cardiovascular and psychiatric diseases are leading causes of morbidity and mortality worldwide. Cardiovascular adverse events related to psychopharmacology have been well-known for decades. They increase the cardio-metabolic risk factor profile. Obesity, hypertension, diabetes mellitus (DM), and dyslipidemia are highly prevalent among patients with psychiatric disorders. Clozapine and olanzapine are known to cause severe hypertriglyceridemia. \u0000Drugs, such as aripiprazole, clozapine, olanzapine, and ziprasidone, increase the prevalence of hypertension, and atypical antipsychotics are known to cause orthostatic hypotension. The most common and popular arrhythmia, Torsades de pointes, due to QT prolongation, is a known side effect of typical and atypical antipsychotics. Sudden deaths, myocarditis, and cardiomyopathies are other common cardiac side effects of psycopharmacotherapy. \u0000Thus, pharmacovigilance is more important for both psychiatrists and cardiologists/physicians when evaluating patients with these common presentations and not to miss the etiological agents.\u0000","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"26 2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81574898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Impact of SSRI Use on the Clinical Outcome and Prognosis of COVID-19 Patients: A Single-Center Prospective Study SSRI使用对COVID-19患者临床结局和预后的影响:一项单中心前瞻性研究
Pub Date : 2022-10-27 DOI: 10.2174/2211556011666221027124605
F. Boroujerdi, M. Safa, S. Ziai, A. Moniri, Farzaneh Haji Zadeh, A. Soheili, Siamak Afaghi, F. Rahimi, Bamdad Mirab Zadeh Ardekani
Recent studies have found a link between the usage of selective serotonin reuptake inhibitors (SSRIs) and a lower mortality rate in COVID-19 cases.The goal of current research was evaluating the effectiveness of SSRI drugs on improvement of COVID-19 patients.This prospective case-control study, compared SSRI-treated patients with matched control patients not treated with SSRIs at Masih Daneshvari Hospital on a population of 350 patients diagnosed with COVID-19 from March 15th 2021 to March 16th 2022.ICU admission rates were significantly more in the control group than in the case group (44.8% vs. 25.9%; p-value=0.0002; Odds Ratio (OR)= 2.32). Intubation was reported for more cases in the control group than the case group (26.7% vs. 11.4%; p-value=0.0002; OR=2.84). Mortality rate was found to be significantly more in the control group than the case group (23.0% vs. 10.8%; p-value=0.0002; OR=2.46). Furthermore, the subgroup analyses on Fluvoxamine and Sertraline showed that Hospitalization period, ICU admission rates, and intubation were all reported to be significantly smaller in each case subgroups as against the control group.Our assessments underlined the potential efficacy of SSRIs in improving COVID-19 patients’ prognosis, since the use of SSRIs were shown to be associated with shorter hospital stay and ICU stay, lower ICU admission rates and intubation rates, and ultimately decreased mortality rates.
最近的研究发现,在COVID-19病例中,选择性血清素再摄取抑制剂(SSRIs)的使用与较低的死亡率之间存在联系。本研究的目的是评估SSRI药物对COVID-19患者改善的有效性。这项前瞻性病例对照研究比较了Masih Daneshvari医院在2021年3月15日至2022年3月16日期间诊断为COVID-19的350名患者中接受ssri治疗的患者和未接受SSRIs治疗的匹配对照患者。对照组ICU住院率明显高于病例组(44.8% vs. 25.9%;假定值= 0.0002;优势比(OR)= 2.32。对照组插管病例数高于病例组(26.7% vs. 11.4%;假定值= 0.0002;或= 2.84)。对照组的死亡率明显高于病例组(23.0% vs 10.8%;假定值= 0.0002;或= 2.46)。此外,氟伏沙明和舍曲林的亚组分析显示,与对照组相比,每个病例亚组的住院时间、ICU住院率和插管率均明显小于对照组。我们的评估强调了SSRIs在改善COVID-19患者预后方面的潜在功效,因为SSRIs的使用与缩短住院时间和ICU住院时间、降低ICU入院率和插管率以及最终降低死亡率相关。
{"title":"The Impact of SSRI Use on the Clinical Outcome and Prognosis of COVID-19 Patients: A Single-Center Prospective Study","authors":"F. Boroujerdi, M. Safa, S. Ziai, A. Moniri, Farzaneh Haji Zadeh, A. Soheili, Siamak Afaghi, F. Rahimi, Bamdad Mirab Zadeh Ardekani","doi":"10.2174/2211556011666221027124605","DOIUrl":"https://doi.org/10.2174/2211556011666221027124605","url":null,"abstract":"\u0000\u0000Recent studies have found a link between the usage of selective serotonin reuptake inhibitors (SSRIs) and a lower mortality rate in COVID-19 cases.\u0000\u0000\u0000\u0000The goal of current research was evaluating the effectiveness of SSRI drugs on improvement of COVID-19 patients.\u0000\u0000\u0000\u0000This prospective case-control study, compared SSRI-treated patients with matched control patients not treated with SSRIs at Masih Daneshvari Hospital on a population of 350 patients diagnosed with COVID-19 from March 15th 2021 to March 16th 2022.\u0000\u0000\u0000\u0000ICU admission rates were significantly more in the control group than in the case group (44.8% vs. 25.9%; p-value=0.0002; Odds Ratio (OR)= 2.32). Intubation was reported for more cases in the control group than the case group (26.7% vs. 11.4%; p-value=0.0002; OR=2.84). Mortality rate was found to be significantly more in the control group than the case group (23.0% vs. 10.8%; p-value=0.0002; OR=2.46). Furthermore, the subgroup analyses on Fluvoxamine and Sertraline showed that Hospitalization period, ICU admission rates, and intubation were all reported to be significantly smaller in each case subgroups as against the control group.\u0000\u0000\u0000\u0000Our assessments underlined the potential efficacy of SSRIs in improving COVID-19 patients’ prognosis, since the use of SSRIs were shown to be associated with shorter hospital stay and ICU stay, lower ICU admission rates and intubation rates, and ultimately decreased mortality rates.\u0000","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75337587","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Exploratory Study Using the Anti-Anxiety Medication Buspirone for Driving Anxiety in Autism Spectrum Disorder 抗焦虑药物丁螺环酮对自闭症谱系障碍患者焦虑驱动的探索性研究
Pub Date : 2022-08-17 DOI: 10.2174/2211556011666220817090452
R. Fried, Maura Di Salvo, Bruce Mehler, Thomas McWilliams, Haley Driscoll, Chloe Hutt Vater, J. Biederman
The literature documents that intellectually capable autism spectrum disorder(ASD) is frequently associated with driving avoidance. Because ASD is associated with high levels ofcomorbid anxiety and our previous work suggested heightened anxiety during driving simulation, weevaluated whether driving behavior assessed through a driving simulator would improve with antianxiety medication.This was an open label, proof of concept, testing the usefulness and tolerability of the nonsedating, short acting anti-anxiety medication buspirone using a randomly assigned crossover design.The sample consisted of 24 adult drivers (5 female) with DSM-V ASD (mean age 28.4years) who completed two simulated driving sessions, one while taking the anti-anxiety medicationbuspirone and one without it.Treatment with buspirone was associated with significantly improved driving performance asmeasured by less variability in lane positioning, a proxy for safer driving, lower self-report anxietyscores on items involving physical sensations, and better self-report scores on the ability to concentrate while driving.These preliminary, proof of concept findings suggest that mitigating anxiety may improve driving performance in individuals with intellectually capable ASD, supporting the need to conduct larger controlled studies assessing this important issue.
文献表明,智性自闭症谱系障碍(ASD)常与驾驶回避有关。因为ASD与高水平的共病焦虑有关,我们之前的工作表明驾驶模拟期间焦虑加剧,我们评估了通过驾驶模拟器评估的驾驶行为是否会通过抗焦虑药物得到改善。这是一个开放的标签,概念证明,使用随机分配的交叉设计测试非镇静,短效抗焦虑药物丁螺环酮的有效性和耐受性。样本包括24名患有DSM-V ASD的成年司机(5名女性)(平均年龄28.4岁),他们完成了两次模拟驾驶,一次服用抗焦虑药物丁螺环酮,另一次不服用。丁螺环酮治疗与驾驶表现的显著改善有关,这可以通过减少车道定位的可变性来衡量,这是一种安全驾驶的代表,在涉及身体感觉的项目上,自我报告的焦虑得分较低,在驾驶时集中注意力的自我报告得分较高。这些初步的概念证明的发现表明,减轻焦虑可能会提高有智力的ASD患者的驾驶表现,支持进行更大规模的对照研究来评估这一重要问题的必要性。
{"title":"An Exploratory Study Using the Anti-Anxiety Medication Buspirone for Driving Anxiety in Autism Spectrum Disorder","authors":"R. Fried, Maura Di Salvo, Bruce Mehler, Thomas McWilliams, Haley Driscoll, Chloe Hutt Vater, J. Biederman","doi":"10.2174/2211556011666220817090452","DOIUrl":"https://doi.org/10.2174/2211556011666220817090452","url":null,"abstract":"\u0000\u0000The literature documents that intellectually capable autism spectrum disorder\u0000(ASD) is frequently associated with driving avoidance. Because ASD is associated with high levels of\u0000comorbid anxiety and our previous work suggested heightened anxiety during driving simulation, we\u0000evaluated whether driving behavior assessed through a driving simulator would improve with antianxiety medication.\u0000\u0000\u0000\u0000This was an open label, proof of concept, testing the usefulness and tolerability of the nonsedating, short acting anti-anxiety medication buspirone using a randomly assigned crossover design.\u0000\u0000\u0000\u0000The sample consisted of 24 adult drivers (5 female) with DSM-V ASD (mean age 28.4\u0000years) who completed two simulated driving sessions, one while taking the anti-anxiety medication\u0000buspirone and one without it.\u0000\u0000\u0000\u0000Treatment with buspirone was associated with significantly improved driving performance as\u0000measured by less variability in lane positioning, a proxy for safer driving, lower self-report anxiety\u0000scores on items involving physical sensations, and better self-report scores on the ability to concentrate while driving.\u0000\u0000\u0000\u0000These preliminary, proof of concept findings suggest that mitigating anxiety may improve driving performance in individuals with intellectually capable ASD, supporting the need to conduct larger controlled studies assessing this important issue.\u0000","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"18 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78303326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive Review on Ethnopharmacological and Phytochemical Aspects of Nutraceuticals in Psychiatric Disorders 精神疾病营养药品的民族药理学和植物化学方面的综合综述
Pub Date : 2022-05-10 DOI: 10.2174/2211556011666220510141329
Samir G Patel, Niraj Vyas, Alkesh Patel, Umang Shah, M. Raval, Mehul Patel, Archita J Patel
Ageing comes with degeneration in many biological activities like impairment of cognition, intelligence, attention, and memory. The decline in all those mental capabilities would be due to the abnormal changes in neuronal architecture with increasing age, chronic oxidative stress and inflammatory state of the tissue, nutritional deficiency. Nootropics or smart drugs enhance memory, attention, creativity, and cognitive performance by affecting the synthesis and receptor binding of neurotransmitters in the brain, especially dopamine, serotonin, gamma-aminobutyric acid, glutamate, and acetylcholine. Nootropics have shown their positive effects in parkinson's, autism, alzheimer's, huntington's disorders, where impaired memory is the primary concern. Synthetic class of nootropics has limitations and reported exacerbation of other brain disorders (off label effects) or therapeutic failure in some instances. Nutraceuticals are dietary derived vitamins, minerals, herbal products, proteins, marine products, and probiotics. The health benefits derived from Nutraceuticals are increasing brain blood flow, reducing inflammation in nervous tissues, detoxifying toxins from the brain, balancing neurotransmitter turnover rate, correcting neuronal and receptor damages and facilitating synaptic transmission, good antioxidant properties and power of improving neuroplasticity of the brain that combat neurodegeneration. The demands for effective nootropics will remain high as the number of cases are increased tremendously.
衰老伴随着许多生物活动的退化,如认知、智力、注意力和记忆力的损害。所有这些智力能力的下降可能是由于随着年龄的增长,神经元结构的异常变化,组织的慢性氧化应激和炎症状态,营养缺乏。益智药或智能药物通过影响大脑中神经递质的合成和受体结合来增强记忆力、注意力、创造力和认知能力,尤其是多巴胺、血清素、γ -氨基丁酸、谷氨酸和乙酰胆碱。益智药对帕金森氏症、自闭症、阿尔茨海默氏症、亨廷顿氏症有积极作用,这些疾病的主要问题是记忆受损。合成类益智药有局限性,据报道会加重其他脑部疾病(标签外效应)或在某些情况下治疗失败。营养保健品是膳食来源的维生素、矿物质、草药产品、蛋白质、海洋产品和益生菌。营养保健品的健康益处是增加脑血流量,减少神经组织的炎症,从大脑中排毒,平衡神经递质周转率,纠正神经元和受体损伤,促进突触传递,良好的抗氧化特性和改善大脑神经可塑性的能力,对抗神经变性。由于病例数量急剧增加,对有效益智药的需求仍将很高。
{"title":"Comprehensive Review on Ethnopharmacological and Phytochemical Aspects of Nutraceuticals in Psychiatric Disorders","authors":"Samir G Patel, Niraj Vyas, Alkesh Patel, Umang Shah, M. Raval, Mehul Patel, Archita J Patel","doi":"10.2174/2211556011666220510141329","DOIUrl":"https://doi.org/10.2174/2211556011666220510141329","url":null,"abstract":"\u0000\u0000Ageing comes with degeneration in many biological activities like impairment of cognition, intelligence, attention, and memory. The decline in all those mental capabilities would be due to the abnormal changes in neuronal architecture with increasing age, chronic oxidative stress and inflammatory state of the tissue, nutritional deficiency. Nootropics or smart drugs enhance memory, attention, creativity, and cognitive performance by affecting the synthesis and receptor binding of neurotransmitters in the brain, especially dopamine, serotonin, gamma-aminobutyric acid, glutamate, and acetylcholine. Nootropics have shown their positive effects in parkinson's, autism, alzheimer's, huntington's disorders, where impaired memory is the primary concern. Synthetic class of nootropics has limitations and reported exacerbation of other brain disorders (off label effects) or therapeutic failure in some instances. Nutraceuticals are dietary derived vitamins, minerals, herbal products, proteins, marine products, and probiotics. The health benefits derived from Nutraceuticals are increasing brain blood flow, reducing inflammation in nervous tissues, detoxifying toxins from the brain, balancing neurotransmitter turnover rate, correcting neuronal and receptor damages and facilitating synaptic transmission, good antioxidant properties and power of improving neuroplasticity of the brain that combat neurodegeneration. The demands for effective nootropics will remain high as the number of cases are increased tremendously.\u0000","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75557249","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cocaine administration protects gut mucosa barrier and reduces plasma level of TNF-α. 服用可卡因可保护肠道粘膜屏障,降低血浆中 TNF-α 的水平。
Pub Date : 2022-01-01 Epub Date: 2022-09-12 DOI: 10.2174/2211556011666220818091709
Xiaoyu Fu, Chuanxiu Bian, Anna Kruyer, Zejun Zhou, Zhenwu Luo, Azizul Haque, Amanda Wagner, Ren Lang, Sylvia Fitting, Catrina Robinson, Aimee McRae-Clark, Davide Amato, Wei Jiang

Background: Cocaine affects not only the central nervous system, but also systemic immunity. The role of cocaine in gut mucosal integrity is not fully understood.

Methods: Here we evaluated the effect of cocaine use on gut endothelial permeability and system inflammation in rats that self-administered cocaine or saline and in humans using immunohistochemistry, qPCR, ELISA, and Transepithelial/transendothelial electrical resistance (TEER).

Results: Cocaine administration maintained intact and undisturbed intestinal mucosal structures, increased tight junction claudin 1 and 2 mRNA expression, and decreased plasma TNF-α levels, compared to the control group, at the end of study in rats. Further, cocaine treatment decreased gut endothelial permeability in a dose-dependent manner in human epithelial Caco-2 cells in vitro. Consistently, chronic cocaine users exhibited decreased plasma levels of TNF-α compared with non-drug users in vivo. However, plasma IL-6 levels were similar between cocaine use and control groups both in humans and rats in vivo.

Conclusions: Our results from both human and rat studies in vivo and in vitro suggest that cocaine use may exert a protective effect on the integrity of gut mucosa and suppresses plasma TNF-α levels. This study may provide information on some beneficial effects of cocaine use on gut endothelial cells integrity and systemic inflammation.

背景:可卡因不仅会影响中枢神经系统,还会影响全身免疫系统。方法:在此,我们使用免疫组化、qPCR、ELISA 和跨上皮/跨内皮细胞电阻(TEER)评估了可卡因使用对自我注射可卡因或生理盐水的大鼠以及人类肠道内皮通透性和系统炎症的影响:结果:与对照组相比,大鼠在研究结束时服用可卡因能保持肠粘膜结构完整无损,增加紧密连接claudin 1和2 mRNA的表达,降低血浆TNF-α水平。此外,在体外人上皮 Caco-2 细胞中,可卡因治疗以剂量依赖的方式降低了肠道内皮的通透性。与不服用可卡因的人相比,长期服用可卡因的人体内血浆中 TNF-α 的水平有所下降。然而,在人和大鼠体内,使用可卡因组和对照组的血浆 IL-6 水平相似:我们对人类和大鼠体内和体外研究的结果表明,吸食可卡因可能会对肠道粘膜的完整性产生保护作用,并抑制血浆 TNF-α 的水平。这项研究可提供有关使用可卡因对肠道内皮细胞完整性和全身炎症的一些有益影响的信息。
{"title":"Cocaine administration protects gut mucosa barrier and reduces plasma level of TNF-α.","authors":"Xiaoyu Fu, Chuanxiu Bian, Anna Kruyer, Zejun Zhou, Zhenwu Luo, Azizul Haque, Amanda Wagner, Ren Lang, Sylvia Fitting, Catrina Robinson, Aimee McRae-Clark, Davide Amato, Wei Jiang","doi":"10.2174/2211556011666220818091709","DOIUrl":"10.2174/2211556011666220818091709","url":null,"abstract":"<p><strong>Background: </strong>Cocaine affects not only the central nervous system, but also systemic immunity. The role of cocaine in gut mucosal integrity is not fully understood.</p><p><strong>Methods: </strong>Here we evaluated the effect of cocaine use on gut endothelial permeability and system inflammation in rats that self-administered cocaine or saline and in humans using immunohistochemistry, qPCR, ELISA, and Transepithelial/transendothelial electrical resistance (TEER).</p><p><strong>Results: </strong>Cocaine administration maintained intact and undisturbed intestinal mucosal structures, increased tight junction claudin 1 and 2 mRNA expression, and decreased plasma TNF-α levels, compared to the control group, at the end of study in rats. Further, cocaine treatment decreased gut endothelial permeability in a dose-dependent manner in human epithelial Caco-2 cells <i>in vitro</i>. Consistently, chronic cocaine users exhibited decreased plasma levels of TNF-α compared with non-drug users <i>in vivo</i>. However, plasma IL-6 levels were similar between cocaine use and control groups both in humans and rats <i>in vivo</i>.</p><p><strong>Conclusions: </strong>Our results from both human and rat studies <i>in vivo</i> and <i>in vitro</i> suggest that cocaine use may exert a protective effect on the integrity of gut mucosa and suppresses plasma TNF-α levels. This study may provide information on some beneficial effects of cocaine use on gut endothelial cells integrity and systemic inflammation.</p>","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"11 2","pages":"1-8"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9974179/pdf/nihms-1832033.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10866122","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dopaminylation in Psychostimulant Use Disorder Protects Against Psychostimulant Seeking Behavior by Normalizing Nucleus Accumbens (NAc) Dopamine Expression. 精神兴奋剂使用障碍中的多巴胺化通过使伏隔核(NAc)多巴胺表达正常化来防止寻求精神兴奋剂的行为。
Pub Date : 2022-01-01 Epub Date: 2021-01-08 DOI: 10.2174/2211556009666210108112737
Kenneth Blum, Mark S Gold, Jean L Cadet, David Baron, Abdalla Bowirrat, Panayotis K Thanos, Raymond Brewer, Rajendra D Badgaiyan, Marjorie C Gondré-Lewis

Background: Repeated cocaine administration changes histone acetylation and methylation on Lys residues and Deoxyribonucleic acid (DNA) within the nucleus accumbens (NAc). Recently Nestler's group explored histone Arg (R) methylation in reward processing models. Damez-Werno et al. (2016) reported that during human investigations and animal self-administration experiments, the histone mark protein-R-methyltransferase-6 (PRMT6) and asymmetric dimethylation of R2 on histone H3 (H3R2me2a) decreased in the rodent and cocaine-dependent human NAc. Overexpression of PRMT6 in D2-MSNs in all NAc neurons increased cocaine seeking, whereas PRMT6 overexpression in D1-MSNs protects against cocaine-seeking.

Hypothesis: The hypothesis is that dopaminylation (H3R2me2a binding) occurs in psychostimulant use disorder (PSU), and the binding inhibitor Srcin1, like the major DRD2 A2 allelic polymorphism, protects against psychostimulant seeking behavior by normalizing nucleus accumbens (NAc) dopamine expression.

Discussion: Numerous publications confirmed the association between the DRD2 Taq A1 allele (30-40 lower D2 receptor numbers) and severe cocaine dependence. Lepack et al. (2020) found that acute cocaine increases dopamine in NAc synapses, and results in histone H3 glutamine 5 dopaminylation (H3Q5dop) and consequent inhibition of D2 expression. The inhibition increases with chronic cocaine use and accompanies cocaine withdrawal. They also found that the Src kinase signaling inhibitor 1 (Srcin1 or p140CAP) during cocaine withdrawal reduced H3R2me2a binding. Consequently, this inhibited dopaminylation induced a "homeostatic brake."

Conclusion: The decrease in Src signaling in NAc D2-MSNs, (like the DRD2 Taq A2 allele, a well-known genetic mechanism protective against SUD) normalizes the NAc dopamine expression and decreases cocaine reward and motivation to self-administer cocaine. The Srcin1 may be an important therapeutic target.

背景:反复给药可改变伏隔核(NAc)内赖氨酸残基和脱氧核糖核酸(DNA)的组蛋白乙酰化和甲基化。最近Nestler的团队探索了组蛋白Arg (R)甲基化在奖励处理模型中的作用。Damez-Werno等人(2016)报道,在人类研究和动物自我给药实验中,组蛋白标记蛋白r -甲基转移酶-6 (PRMT6)和组蛋白H3 (H3R2me2a)上R2的不对称二甲基化在啮齿动物和可卡因依赖的人类NAc中减少。所有NAc神经元D2-MSNs中PRMT6的过表达增加了可卡因寻求,而D1-MSNs中PRMT6的过表达可防止可卡因寻求。假设:假设多巴胺化(H3R2me2a结合)发生在精神兴奋剂使用障碍(PSU)中,而结合抑制剂Srcin1,像主要的DRD2 A2等位基因多态性一样,通过使伏隔核(NAc)多巴胺表达正常化来防止寻求精神兴奋剂的行为。讨论:许多出版物证实了DRD2 Taq A1等位基因(D2受体数量低30-40)与严重可卡因依赖之间的关联。Lepack等人(2020)发现急性可卡因增加NAc突触中的多巴胺,导致组蛋白H3谷氨酰胺5多巴胺化(H3Q5dop),从而抑制D2表达。这种抑制作用随着长期使用可卡因和戒断可卡因而增强。他们还发现,在可卡因戒断期间,Src激酶信号抑制剂1 (Srcin1或p140CAP)减少了H3R2me2a的结合。因此,这种抑制多巴胺化诱导了“稳态制动”。结论:NAc d2 - msn中Src信号的减少(如DRD2 Taq A2等位基因,一种众所周知的预防SUD的遗传机制)使NAc多巴胺表达正常化,降低可卡因奖励和自我使用可卡因的动机。Srcin1可能是一个重要的治疗靶点。
{"title":"Dopaminylation in Psychostimulant Use Disorder Protects Against Psychostimulant Seeking Behavior by Normalizing Nucleus Accumbens (NAc) Dopamine Expression.","authors":"Kenneth Blum,&nbsp;Mark S Gold,&nbsp;Jean L Cadet,&nbsp;David Baron,&nbsp;Abdalla Bowirrat,&nbsp;Panayotis K Thanos,&nbsp;Raymond Brewer,&nbsp;Rajendra D Badgaiyan,&nbsp;Marjorie C Gondré-Lewis","doi":"10.2174/2211556009666210108112737","DOIUrl":"https://doi.org/10.2174/2211556009666210108112737","url":null,"abstract":"<p><strong>Background: </strong>Repeated cocaine administration changes histone acetylation and methylation on Lys residues and Deoxyribonucleic acid (DNA) within the nucleus accumbens (NAc). Recently Nestler's group explored histone Arg (R) methylation in reward processing models. Damez-Werno <i>et al.</i> (2016) reported that during human investigations and animal self-administration experiments, the histone mark protein-R-methyltransferase-6 (PRMT6) and asymmetric dimethylation of R2 on histone H3 (H3R2me2a) decreased in the rodent and cocaine-dependent human NAc. Overexpression of PRMT6 in D2-MSNs in all NAc neurons increased cocaine seeking, whereas PRMT6 overexpression in D1-MSNs protects against cocaine-seeking.</p><p><strong>Hypothesis: </strong>The hypothesis is that dopaminylation (H3R2me2a binding) occurs in psychostimulant use disorder (PSU), and the binding inhibitor Srcin1, like the major DRD2 A2 allelic polymorphism, protects against psychostimulant seeking behavior by normalizing nucleus accumbens (NAc) dopamine expression.</p><p><strong>Discussion: </strong>Numerous publications confirmed the association between the DRD2 <b><i>Taq A1</i></b> allele (30-40 lower D2 receptor numbers) and severe cocaine dependence. Lepack <i>et al.</i> (2020) found that acute cocaine increases dopamine in NAc synapses, and results in histone H3 glutamine 5 dopaminylation (H3Q5dop) and consequent inhibition of D2 expression. The inhibition increases with chronic cocaine use and accompanies cocaine withdrawal. They also found that the Src kinase signaling inhibitor 1 (Srcin1 or p140CAP) during cocaine withdrawal reduced H3R2me2a binding. Consequently, this inhibited dopaminylation induced a \"homeostatic brake.\"</p><p><strong>Conclusion: </strong>The decrease in Src signaling in NAc D2-MSNs, (like the DRD2 Taq A2 allele, a well-known genetic mechanism protective against SUD) normalizes the NAc dopamine expression and decreases cocaine reward and motivation to self-administer cocaine. The Srcin1 may be an important therapeutic target.</p>","PeriodicalId":10751,"journal":{"name":"Current Psychopharmacology","volume":"11 1","pages":"11-17"},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426774/pdf/nihms-1668752.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40336360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 7
期刊
Current Psychopharmacology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1